MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Account Payables
Amounts the company owes suppliers for goods and services received.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables remains negative
Q1 FY2026 account payables was $0, compared with $862K a year earlier.
Context
- Account payables amounted to 0.0% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Account payables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 1.91M | -41.2% |
| FY2023 | 2023-12-31 | 3.25M | -9.6% |
| FY2022 | 2022-12-31 | 3.6M | — |
Account Payables vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 account payables of $0 is the lowest of the 11 companies compared; the peer median is $5.89M.
- Its year-over-year change of -100.0% is the lowest of 10, against a peer median of +143.4%.
- Account payables amounts to 0.0% of total assets for MPLT, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $11.69M | — | -11.8% | 4.2% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $9.28M | +14.3% | +36.3% | 0.9% |
| Mar 2026 | $8.88M | +355.2% | +0.1% | 3.9% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $7.12M | +1021.1% | +138.9% | 1.8% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $6.56M | +206.7% | +42.4% | 1.3% |
| Mar 2026 | $5.21M | +9.2% | +26.4% | 1.9% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $5.06M | +380.7% | -22.1% | 3.3% |
| Mar 2026 | $3.37M | +143.4% | +5.4% | 1.2% | |
| Dec 2025 | $2.64M | -42.2% | +3.6% | 2.0% | |
| Jun 2026 | $1.45M | +61.5% | -13.0% | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding MPLT) | $5.89M | +143.4% | +4.5% | 1.9% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.